Study long-term safety of a prostate cancer drug
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial checks the long-term safety (how it affects you over time) of lutetium-177 vipivotide tetraxetan in people with prostate cancer. You may be eligible if you already received the related drug in a prior Novartis prostate cancer study and can complete the required follow-up tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign an informed consent form before joining.
- You must have already received at least one dose of AAA617 in a Novartis prostate cancer study.
- You must have completed the prior study requirements that allowed you to enter this long-term safety follow-up.
- You must be able to complete all required study check-ups and examinations.
- If you cannot complete the needed tests for any reason, you cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
This study tests a new treatment called 177Lu-PSMA given after standard therapy (surgery or radiation) to see if it can prevent prostate cancer from coming back. It is for patients with high or very high-risk prostate cancer that hasn't spread yet.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
This study tracks people with advanced prostate cancer who are getting a new treatment called lutetium (177Lu) vipivotide tetraxetan. The goal is to gather real-world information about how this treatment works and how safe it is.
This study is observing how well the treatment lutetium-177-PSMA-617 works in people with metastatic castration-resistant prostate cancer. It aims to gather real-world information about its effectiveness and safety.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.